Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03971071 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 620
- Enrollment target
NCT03971071 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 620 participants.
The verdict
NCT03971071, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 620 participants
- Enrollment target
Study Summary
Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication overuse headache (MOH).
Interventions
- DRUG Placebo
- DRUG Erenumab 70 mg
- DRUG Erenumab 140 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2019-10-07 |
| Est. Completion | 2023-06-13 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03971071
The ClinicalTrials.gov registry entry for NCT03971071 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 620 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03971071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03971071 about?
NCT03971071 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache". Study 20170703 is a phase 4, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of erenumab against placebo in participants with chronic migraine (CM) who have a history of at least 1 preventive treatment failure and are diagnosed with medication o...
What is the current status of trial NCT03971071?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 620 participants. The study started on 2019-10-07. Estimated completion is 2023-06-13.
What interventions are being tested in trial NCT03971071?
The interventions under investigation include: Placebo (DRUG), Erenumab 70 mg (DRUG), Erenumab 140 mg (DRUG).
Who is sponsoring clinical trial NCT03971071?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.